2022
DOI: 10.1093/neuonc/noac209.201
|View full text |Cite
|
Sign up to set email alerts
|

Radt-11. Clinical Outcomes in the Management of Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Anti-Pd-1+ctla-4

Abstract: BACKGROUND Anti-PD-1+CTLA-4 therapy has revolutionized melanoma brain metastases (MBM) treatment. Prospective trials show higher response in asymptomatic versus symptomatic patients. We evaluated clinical outcomes in MBM treated with stereotactic radiosurgery (SRS) and anti-PD-1+CTLA-4. METHODS Patients were included if MBM were diagnosed and treated with SRS within 3 months of anti-PD-1+CTLA-4, and this was their last course… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles